about
Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA.The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial FibrillationHemodynamic and biologic determinates of arteriovenous fistula outcomes in renal failure patientsAsymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosisFXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl ratsEndothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endotheliumProton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General PopulationSymmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis.The issue of plasma asymmetric dimethylarginine reference range - A systematic review and meta-analysisKidney dysfunction in patients with pulmonary arterial hypertensionArginine/Asymmetric Dimethylarginine Ratio in Colorectal Surgery.Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine.Short-term physical inactivity impairs vascular function.Changes in ADMA/DDAH pathway after hepatic ischemia/reperfusion injury in rats: the role of bileDevelopment of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screening.IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapyThe association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine.Abdominal obesity is associated with peripheral artery disease in hemodialysis patients.The Role of Obesity in Preeclampsia.The endotoxin/toll-like receptor-4 axis mediates gut microvascular dysfunction associated with post-prandial lipidemia.Role of nitric oxide signaling in endothelial differentiation of embryonic stem cellsAdd-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized StudyAsymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease.Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivityAngiogenesis and the role of the endothelial nicotinic acetylcholine receptor.L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure.Symmetric dimethylarginine as a proinflammatory agent in chronic kidney diseaseAsymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.Proton pump inhibitors and vascular function: A prospective cross-over pilot studyNitric oxide status in patients with chronic kidney disease.Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality.Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).ADMA metabolism and clearance.Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolismAsymmetric dimethylarginine induces endothelial nitric-oxide synthase mitochondrial redistribution through the nitration-mediated activation of Akt1Effect of resistance training on plasma nitric oxide and asymmetric dimethylarginine concentrations in type I diabetic ratsHigh levels of asymmetric dimethylarginine are strongly associated with low HDL in patients with acute myocardial infarction.
P2860
Q24810521-ACD79A7E-E7AB-43E5-BB67-F83224576100Q26747263-3752666F-3882-4F6C-83CA-4739741EE2AEQ26780134-EB6AF4A4-340B-4E16-BD8A-F7DCB840E518Q26795604-FD357B3A-1556-46E6-8EC4-9042ED265125Q27329677-2F7B4D74-03B0-4799-BE64-6C9B19668892Q28219326-83A87474-6603-4BC6-A184-A289E5B59CDBQ28548045-28A6FDB4-A45D-4376-A1E5-F26CFB227A4DQ33246409-4E29C827-3E35-46DC-8632-4DEEA9E599A1Q33664224-4E665100-5A10-4179-B23E-89FD721366F4Q33738621-887329E3-37FA-4820-8E8E-38A4DFB858B2Q33763284-8ACBA22C-5F67-4FFC-B649-BC3BE27ED4A1Q33816492-F4E3820B-25C8-42DF-82D7-239A2AFB2ABDQ33896015-D8D83214-1374-49D1-B05E-6D55F26C2504Q34162190-B537FC53-80B7-4CA8-8DC1-B00765ABAB6EQ34213198-57C0759F-EAB9-4BB1-A88A-2569706CCB84Q34250990-BC0684DA-DE0B-4715-9E88-540E1E25D59EQ34755672-D53B4480-8259-4FB4-913E-9F750286649DQ34807672-DDAF7814-1B4B-419D-A63A-BBC2E70F9F1DQ34853745-CFA75388-C0BD-4C37-9B83-BFEFDF4C92B1Q35039428-DEB86EE3-361B-4E52-AFBB-B883CF2C80ABQ35064180-6292F55E-0774-4E4A-9785-1D294AB84585Q35072453-830F9F94-952F-498A-91E0-C0B24786615DQ35090446-332FDC6C-087A-478A-9BC7-E2AE8CC638A3Q35190437-78FE37A3-1EDF-4758-AC08-EB8D5F54A6ABQ35928726-96B139F2-A592-4FAF-B044-B12055557262Q35961528-6B8787D8-3428-4DCB-A06A-EE9FD225A205Q35985806-2A940EEA-C04A-459A-AE11-CF32E8F13B9DQ36018553-9F2DB76E-9F64-4FC9-947E-D8360FAAF824Q36067712-E2B2018E-DDE0-485D-B00C-E0E9E7623423Q36106127-2B1E0BC1-C68E-442C-801C-E54CE4D51DB9Q36273352-5ABAAB11-5840-49B3-8D61-501B7901377EQ36381000-9A44DC07-3FDF-410B-98B9-34BC241FE166Q36381003-09874A44-FA89-40FC-9F99-98764EEE72D5Q36381009-5CCCEE2B-8A07-4A9F-AA36-196C4D1A3AE0Q36381017-344E7E73-1113-4C9D-B16E-B27FBDD9AF35Q36438224-D458F64E-110B-420A-A57A-A0C337602C6CQ36536026-206D4282-5CC7-4DBD-8810-C3AEC1C479D2Q36647252-0E66661A-914A-42D9-A66F-E0E31851F774Q36879357-B3E6730B-EC17-4314-A969-A47B79B994B7Q36908856-A564E266-3DF4-41BB-B8D5-9EDF75C9E469
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Asymmetrical dimethylarginine: the Uber marker?
@ast
Asymmetrical dimethylarginine: the Uber marker?
@en
Asymmetrical dimethylarginine: the Uber marker?
@nl
type
label
Asymmetrical dimethylarginine: the Uber marker?
@ast
Asymmetrical dimethylarginine: the Uber marker?
@en
Asymmetrical dimethylarginine: the Uber marker?
@nl
prefLabel
Asymmetrical dimethylarginine: the Uber marker?
@ast
Asymmetrical dimethylarginine: the Uber marker?
@en
Asymmetrical dimethylarginine: the Uber marker?
@nl
P1433
P1476
Asymmetrical dimethylarginine: the Uber marker?
@en
P2093
John P Cooke
P304
P356
10.1161/01.CIR.0000126823.07732.D5
P407
P577
2004-04-01T00:00:00Z